Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer-Reference-Cited by-同舟云学术

Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer

Published:2018-03-25 Issue:5 Volume:7 Page:1794-1801
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Nishimura Shuichi¹^ORCID,Ohashi Toshio¹,Momma Tetsuo²,Sakayori Masanori¹,Eriguchi Takahisa¹,Tanaka Tomoki¹,Yamashita Shoji³,Kosaka Takeo⁴,Oya Mototsugu⁴,Shigematsu Naoyuki¹

Affiliation:

1. Department of Radiology; Keio University School of Medicine; Tokyo Japan

2. Department of Urology; National Hospital Organization Saitama Hospital; Saitama Japan

3. Department of Radiology; National Hospital Organization Saitama Hospital; Saitama Japan

4. Department of Urology; Keio University School of Medicine; Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference28 articles.

1. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer;Hanlon;Int. J. Radiat. Oncol. Biol. Phys.,2002

2. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis;Ray;Int. J. Radiat. Oncol. Biol. Phys.,2006